XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date
XOMA Royalty Corp. said its board authorized quarterly dividends on its preferred stock: $0.53906 per share for the 8.625% Series A (XOMAP) and $0.52344 per depositary share for the 8.375% Series B (XOMAO). Dividends are payable about July 15, 2026 to holders of record July 2. The company will redeem all outstanding preferred stock on July 14, 2026 at $25.00 per share/depositary share, with dividends stopping after redemption. The redemption is tied to XOMA’s pending merger with Flex Merger Sub,
How this was made
The 30-second read
Why it matters
Traders can map cash flows and eligibility dates: preferred dividends accrue through the redemption date (dividends cease after July 14), while common holders of record on July 13 receive one CVR per share as additional merger consideration.
Market read
Near-term, date-specific corporate actions (preferred redemption + CVR record date) create tradable event windows for XOMA and its rights-related instruments.
What to watch
Liquidity/settlement mechanics (DTCC processing) and how brokers handle record-date eligibility can drive short-lived price dislocations that are not captured by fundamental valuation.
Background
XOMA is in a pending merger with Ligand (Flex Merger Sub into XOMA) and this release sets preferred-stock dividend/redemption terms plus the CVR record date for contingent payments tied to the Janssen Litigation trust.
Ticker impact
XOMA authorized dividends on its preferred stock and will redeem all outstanding preferred shares on July 14, 2026 tied to the pending Ligand merger.
Likely modest, event-driven volatility around the July 2 record date and July 13 CVR record date; direction depends on how the market values the CVRs versus redemption cash.
The article discloses specific dividend amounts, redemption date/price, and the CVR record date tied to the Janssen Litigation trust—actionable for rights/CVR positioning, but it does not provide deal economics or regulatory/closing updates.
Market effects
Reinforces that biotech M&A structures can include CVRs linked to litigation-derived royalty interests, which may influence how traders price contingent consideration in similar deals.
Primarily US-listed biotech capital markets; no direct regional spillover beyond US rights/CVR trading.
Limited global relevance; contingent litigation-linked consideration is deal-specific.
Counterpoint
The preferred redemption is largely mechanical and may not move common stock much if the market already priced the merger/CVR structure; focus may be on deal-close probability rather than dividend/CVR dates.
Key entities
- companyXOMA Royalty Corporation
Declares preferred dividends, announces July 14, 2026 redemption of all outstanding preferred shares, and sets July 13, 2026 CVR record date.
- companyLigand Pharmaceuticals Incorporated
Named party in the pending merger agreement with XOMA; CVRs are tied to the merger consideration structure.
- asset/legal matterXOMA Royalty LLC / Janssen Litigation
CVRs derive from the trust’s 75% interest related to the Janssen Litigation, per the merger agreement.
